The European Medicines Agency review meeting in London on 30 June passed with scarcely a mention of devices and diagnostics.
This was perhaps as expected, given that the meeting, held to examine the outcomes of the assessment of Ernst & Young's Evaluation of the EMA report (January 2010), was focused mainly on the centralised procedure, resources available and future sustainability...
Please login to read the full article.
